3350 logo

Aadi Bioscience DB:3350 Stock Report

Last Price

€2.12

Market Cap

€54.0m

7D

8.2%

1Y

-50.5%

Updated

22 Nov, 2024

Data

Company Financials +

3350 Stock Overview

A biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. More details

3350 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Aadi Bioscience, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aadi Bioscience
Historical stock prices
Current Share PriceUS$2.12
52 Week HighUS$4.82
52 Week LowUS$1.18
Beta0.37
11 Month Change13.98%
3 Month Change54.74%
1 Year Change-50.47%
33 Year Change-89.40%
5 Year Changen/a
Change since IPO-89.87%

Recent News & Updates

Recent updates

Shareholder Returns

3350DE BiotechsDE Market
7D8.2%0.8%-1.3%
1Y-50.5%-17.5%7.4%

Return vs Industry: 3350 underperformed the German Biotechs industry which returned -17.5% over the past year.

Return vs Market: 3350 underperformed the German Market which returned 7.4% over the past year.

Price Volatility

Is 3350's price volatile compared to industry and market?
3350 volatility
3350 Average Weekly Movement6.0%
Biotechs Industry Average Movement6.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.8%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 3350 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 3350's weekly volatility has decreased from 11% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200753Dave Lennonaadibio.com

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.

Aadi Bioscience, Inc. Fundamentals Summary

How do Aadi Bioscience's earnings and revenue compare to its market cap?
3350 fundamental statistics
Market cap€53.97m
Earnings (TTM)-€59.24m
Revenue (TTM)€24.07m

2.3x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3350 income statement (TTM)
RevenueUS$25.07m
Cost of RevenueUS$52.61m
Gross Profit-US$27.54m
Other ExpensesUS$34.15m
Earnings-US$61.69m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.50
Gross Margin-109.86%
Net Profit Margin-246.06%
Debt/Equity Ratio0%

How did 3350 perform over the long term?

See historical performance and comparison